查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1400581

乳房切片設備市場規模-按產品（針式乳房切片槍、乳房切片引導系統、針和鑷子）、技術（影像引導切片、液體切片）、最終用途-全球預測（2023-2032）

Breast Biopsy Devices Market Size - By Product (Needle Based Breast Biopsy Guns, Breast Biopsy Guidance Systems, Needle, & Forceps), Technique (Image Guided Biopsy, Liquid Biopsy), End-use - Global Forecast (2023-2032)
出版日期: | 出版商: Global Market Insights Inc. | 英文 679 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

由於全球乳癌發生率不斷上升，推動了對先進診斷技術的需求，預計 2023 年至 2032 年間，乳房切片設備市場規模的CAGR將超過 6.8%。根據 NBCC 的數據，2023 年，女性診斷出約 297,790 例新的侵襲性乳癌病例，男性診斷出 2,800 例新病例。

隨著宣傳活動和篩檢計畫變得越來越普遍，醫療保健提供者優先考慮採用先進的活體組織切片設備，以提高乳癌診斷的效率和精確度。

真空輔助活體組織切片和超音波引導活體組織切片等微創技術的發展減少了患者的不適和手術併發症，從而提高了採用率。此外，成像技術的創新以及影像判讀人工智慧（AI）的整合有助於提高診斷準確性，刺激市場成長。

整個乳房切片設備市場根據產品、技術、最終用途和地區進行分類。

在引入非侵入性和高度敏感的診斷方法的支持下，液體活體組織切片細分市場預計將在 2023 年和 2032 年顯著成長。這種創新方法涉及分析循環腫瘤 DNA (ctDNA) 或血液中存在的其他生物標記物，以檢測和監測各種癌症。該技術補充了傳統的組織活體組織切片，為監測治療反應和識別基因突變提供了一種侵入性較小的替代方案。早期檢測能力以及對疾病進展的即時監測正在推動液體活體組織切片的採用。

由於採用精簡高效的乳房切片環境，門診手術中心 (ASC) 將在 2023 年至 2032 年期間為市場帶來可觀的收入。門診手術中心的集中性質可以加快患者周轉速度、減少等待時間並最佳化調度，有助於提高手術效率。此外，由於其便利性、個人化護理和成本效益，患者通常更喜歡 ASC 進行乳房活體組織切片手術。

由於乳癌盛行率不斷上升以及加強早期檢測的持續努力，歐洲乳房切片設備產業規模預計到 2032 年將顯著成長。對女性健康和健全的醫療基礎設施的重視導致複雜的乳房活體組織切片設備的廣泛採用。影像技術和微創活體組織切片技術的整合等技術進步透過提高診斷準確性和患者體驗進一步刺激區域市場成長。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：乳房切片設備產業洞察

  • COVID-19 影響分析
  • 產業生態系統分析
  • 技術景觀
  • 監管環境
  • 產業影響力
    • 成長動力
      • 乳癌發生率增加
      • 乳房切片設備的技術進步
      • 對乳癌篩檢的認知不斷提高
      • 有利的報銷方案
    • 產業陷阱與挑戰
      • 與乳房切片手術相關的高成本
      • 與使用活體組織切片針相關的感染風險
  • 成長潛力分析
  • 波特的分析
  • PESTEL分析

第 4 章：競爭格局

  • 介紹
    • Hologic Inc
    • Devicor Medical Products, Inc. (Danaher Corporation)
    • Becton, Dickinson and Company (BD)
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 戰略展望矩陣

第 5 章：乳房切片設備市場規模與預測：按產品分類，2018-2032 年

  • 主要動向：按產品
  • 乳房切片引導系統
    • 手動的
    • 機器人
  • 乳腺針切片槍
    • 真空輔助活體組織切片 (VAB) 裝置
    • 細針抽吸切片檢查 (FNAB) 裝置
    • 空心針切片檢查 (CNB) 裝置
  • 乳房切片針
    • 一次性的
    • 可重複使用的
  • 乳腺切片鉗
    • 普通活體組織切片鉗
    • 熱活體組織切片鉗
  • 其他產品
    • 刷子
    • 刮匙
    • 拳擊

第 6 章：乳房切片設備市場規模與預測：按技術分類，2018-2032 年

  • 主要動向：按技術
  • 影像引導活體組織切片
    • MRI導引乳房切片檢查
    • 超音波引導乳房切片檢查
    • 乳房X光攝影引導立體定位活體組織切片
    • 其他影像引導活體組織切片
  • 液體活體組織切片
    • 基於NGS的活體組織切片
    • 基於PCR的活體組織切片
    • 基於微陣列的活體組織切片

第 7 章：乳房切片設備市場規模與預測：依最終用途，2018-2032 年

  • 主要動向：依最終用途
  • 醫院
  • 門診手術中心
  • 其他最終用戶

第 8 章：乳房切片設備市場規模與預測：按地區分類，2018-2032 年

  • 主要動向：按地區
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 南非
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區

第 9 章：公司簡介

  • Stryker Corporation
  • Boston Scientific Corporation
  • FUJIFILM Holdings Corporation
  • Argon Medical Devices, Inc
  • Hologic Inc
  • Cook Group Incorporated
  • Becton, Dickinson and Company (BD)
  • Medtronic plc
  • Olympus Corporation
  • Cardinal Health
  • INRAD Inc
  • Danaher Corporation
  • B. Braun Melsungen AGS
簡介目錄
Product Code: 7441

Breast Biopsy Devices Market size is estimated to record a CAGR of over 6.8% between 2023 and 2032, driven by the increasing incidence of breast cancer across the globe propelling the demand for advanced diagnostic technologies. As per NBCC, in 2023, around 297,790 new cases of invasive breast cancer were diagnosed in women, and 2,800 new cases diagnosed in men.

As awareness campaigns and screening programs become more prevalent, healthcare providers prioritize the incorporation of sophisticated biopsy devices to enhance the efficiency and precision of breast cancer diagnosis.

The development of minimally invasive techniques, such as vacuum-assisted biopsy and ultrasound-guided biopsy, reduces patient discomfort and procedural complications, leading to increased adoption. Moreover, innovations in imaging technologies and the integration of artificial intelligence (AI) for image interpretation contribute to higher diagnostic accuracy, stimulating the market growth.

The overall breast biopsy devices market is classified on the basis of product, technique, end-use, and region.

Liquid biopsy segment is poised for a notable growth during 2023 and 2032, backed by introduction of non-invasive and highly sensitive diagnostic methods. This innovative approach involves analyzing circulating tumor DNA (ctDNA) or other biomarkers present in the blood to detect and monitor various cancers. The technique complements traditional tissue biopsies, offering a less invasive alternative for monitoring treatment responses and identifying genetic mutations. The early detection capabilities, along with the real-time monitoring of disease progression is pushing the adoption of liquid biopsy.

Ambulatory surgical centers (ASCs) will generate notable revenues for the market during 2023-2032, favored by streamlined and efficient environment for performing breast biopsies. The focused nature of ambulatory surgical centers allows for quicker patient turnaround, reduced waiting times, and optimized scheduling, contributing to increased procedural efficiency. Moreover, patients often prefer ASCs for breast biopsy procedures due to the convenience, personalized care, and cost-effectiveness.

Europe breast biopsy devices industry size is slated to witness a significant growth through 2032, owing to the increasing prevalence of breast cancer and the continuous efforts to enhance early detection. The emphasis on women's health and robust medical infrastructure is leading to a widespread incorporation of sophisticated breast biopsy devices. Technological advancements, such as the integration of imaging technologies and minimally invasive biopsy techniques, further stimulate regional market growth by improving diagnostic accuracy and patient experience.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definition
  • 1.2 Base estimates & workings
  • 1.3 Forecast calculations
  • 1.4 Data Sources
    • 1.4.1 Primary
    • 1.4.2 Secondary
      • 1.4.2.1 Paid sources
      • 1.4.2.2 Unpaid sources

Chapter 2 Executive Summary

  • 2.1 Global breast biopsy devices market 360 degree synopsis, 2018 - 2032
    • 2.1.1 Regional trends
    • 2.1.2 Product trends
    • 2.1.3 Technique trends
    • 2.1.4 End-use trends

Chapter 3 Breast Biopsy Devices Industry Insights

  • 3.1 COVID- 19 impact analysis
  • 3.2 Industry ecosystem analysis
  • 3.3 Technology landscape
  • 3.4 Regulatory landscape
  • 3.5 Industry impact forces
    • 3.5.1 Growth drivers
      • 3.5.1.1 Increasing incidence of breast cancer
      • 3.5.1.2 Technological advancements in breast biopsy equipment
      • 3.5.1.3 Rising awareness regarding breast cancer screening
      • 3.5.1.4 Favourable reimbursement scenario
    • 3.5.2 Industry pitfalls & challenges
      • 3.5.2.1 High cost associated with breast biopsy procedure
      • 3.5.2.2 Risk of infection associated with the use of biopsy needles
  • 3.6 Growth potential analysis
    • 3.6.1 By product
    • 3.6.2 By technique
    • 3.6.3 By end-use
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

  • 4.1 Introduction
    • 4.1.1 Hologic Inc
    • 4.1.2 Devicor Medical Products, Inc. (Danaher Corporation)
    • 4.1.3 Becton, Dickinson and Company (BD)
  • 4.2 Competitive analysis of major market players, 2022
  • 4.3 Competitive positioning matrix, 2022
  • 4.4 Strategic outlook matrix, 2022

Chapter 5 Breast Biopsy Devices Market Size and Forecast, By Product, 2018-2032 (USD Million & Units)

  • 5.1 Key trends, by product
  • 5.2 Breast biopsy guidance systems
    • 5.2.1 Manual
    • 5.2.2 Robotic
  • 5.3 Needle based breast biopsy guns
    • 5.3.1 Vacuum-assisted biopsy (VAB) devices
    • 5.3.2 Fine needle aspiration biopsy (FNAB) devices
    • 5.3.3 Core needle biopsy (CNB) devices
  • 5.4 Breast biopsy needles
    • 5.4.1 Disposable
    • 5.4.2 Reusable
  • 5.5 Breast biopsy forceps
    • 5.5.1 General biopsy forceps
    • 5.5.2 Hot biopsy forceps
  • 5.6 Other products
    • 5.6.1 Brushes
    • 5.6.2 Curettes
    • 5.6.3 Punches

Chapter 6 Breast Biopsy Devices Market Size and Forecast, By Technique, 2018-2032 (USD Million)

  • 6.1 Key trends, by technique
  • 6.2 Image guided biopsy
    • 6.2.1 MRI guided breast biopsy
    • 6.2.2 Ultrasound guided breast biopsy
    • 6.2.3 Mammography guided stereotactic biopsy
    • 6.2.4 Other image guided biopsies
  • 6.3 Liquid Biopsy
    • 6.3.1 NGS based biopsy
    • 6.3.2 PCR based biopsy
    • 6.3.3 Micro-array based biopsy

Chapter 7 Breast Biopsy Devices Market Size and Forecast, By End-use, 2018-2032 (USD Million)

  • 7.1 Key trends, by end-use
  • 7.2 Hospitals
  • 7.3 Ambulatory surgical centers
  • 7.4 Other end-users

Chapter 8 Breast Biopsy Devices Market Size and Forecast, By Region, 2018-2032 (USD Million & Units)

  • 8.1 Key trends, by region
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Italy
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
    • 8.4.6 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
    • 8.5.4 Rest of Latin America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 South Africa
    • 8.6.3 UAE
    • 8.6.4 Rest of Middle East & Africa

Chapter 9 Company Profiles

  • 9.1 Stryker Corporation
  • 9.2 Boston Scientific Corporation
  • 9.3 FUJIFILM Holdings Corporation
  • 9.4 Argon Medical Devices, Inc
  • 9.5 Hologic Inc
  • 9.6 Cook Group Incorporated
  • 9.7 Becton, Dickinson and Company (BD)
  • 9.8 Medtronic plc
  • 9.9 Olympus Corporation
  • 9.10 Cardinal Health
  • 9.11 INRAD Inc
  • 9.12 Danaher Corporation
  • 9.13 B. Braun Melsungen AGS